ERYTECH Pharma S.A.

Board/Management Information • Jun 18, 2014

PRESS RELEASE ERYTECH appoints two new independent board members

Lyon (France), June 18th, 2014 – ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative 'tumor starvation' treatments for acute leukemia and other oncology indications with unmet medical needs, announces it has appointed Dr Martine George and Mrs Hilde Windels as new independent members to its board of directors.

Martine George, M.D. is a very experienced, US based clinical research, medical affairs and regulatory affairs executive, both in large and small oncology companies. Until recently Dr George was Vice President Global Medical Affairs, Oncology at Pfizer in New York. Her previous functions before Pfizer included Chief Medical Officer at GPC Biotech in Princeton and Head of oncology at Johnson & Johnson in New Jersey. Martine George is a board certified Medical Oncologist and Gynecologist, trained in France and Montréal. She started her career as a clinician as Service Chief at Institut Gustave Roussy in France and as Visiting Professor at Memorial Sloan Kettering Cancer Center in New York.

Hilde Windels has over 20 years' experience in corporate finance, capital markets and strategic initiatives. She is the Chief Financial Oofficer of Biocartis, a molecular diagnostics and immunodiagnostics company based in Belgium and Switzerland. Before Biocartis, Hilde was Devgen's CFO (Euronext: DEVG) from 1999 until the end of 2008 and was member of Devgen's board from 2001 until the end of 2008. From early 2009 to mid 2011, she worked as independent CFO for a few private biotechnology companies, and she sat on the board of MDX Health (Euronext: MDXH) from June 2010 until end of August 2011. Previously, she was responsible at ING for commercial banking in one of the Belgian areas. She holds a degree in Economics from the University of Leuven (Belgium).

"We are delighted and proud to have these seasoned professionals joining our Board of Directors. There respective experiences in oncology drug development and financial affairs will be of great value at this important time for the company. With Phase III data for our lead product expected in a few months, and three other clinical programs ongoing, in Europe and the USA, ERYTECH making its steps to build a strategic value in orphan oncology," comments Gil Beyen, Chairman and CEO of ERYTECH.

About ERYTECH and ERY-ASP/GRASPA®: www.erytech.com

ERYTECH is a French biopharmaceutical company providing new prospects for cancer patients, particularly those with acute leukemia and selected solid tumors. The company is also developing other indications in solid tumors and certain orphan indications outside oncology.

ERYTECH is listed on Euronext regulated market in Paris. (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC All Shares, CAC Healthcare, CAC Pharma & Bio, CAC Small, CAC Mid&Small, CAC All Tradable and Next Biotech indexes. ERYTECH shares are eligible to PEA-PME (French share savings plan for SMEs).

For more information about the Company, please read About ERYTECH and ERY-ASP/GRASPA

Created in Lyon in 2004, ERYTECH is a French biopharmaceutical company providing new prospects for cancer patients, particularly those with acute leukemia and selected solid tumors.

	Mis en forme : Police :Gras
	Mis en forme : Justifié
	Mis en forme : Police :Gras
	Mis en forme : Justifié, Espace Après : 6 pt
	Mis en forme : Justifié
	Mis en forme : Justifié, Espace Après : 6 pt
	Code de champ modifié
	Code de champ modifié

1

By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has developed ERY-ASP/GRASPA®, an original treatment that targets cancer cells through "tumor starvation" while significantly reducing the side effects for patients. ERY-ASP/GRASPA® is currently completing Phase III clinical development in Acute Lymphoblastic Leukemia (ALL) and is in Phase IIb clinical trial in Acute Myeloid Leukemia (AML) in Europe. The product is also in Phase I/II clinical development in ALL in the USA.

Every year about 50,000 patients are diagnosed with Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML), the two forms of acute leukemia. Today, for about 80% of these patients, mainly adults and relapsing patients, current forms of asparaginase cannot be used due to their toxicity. With a presumed improved safety profile, ERY-ASP is being developed to allow all leukemia patients to be treated, even the most fragile ones, representing a market opportunity of more than EUR 1 billion. ERYTECH has concluded licensing and distribution partnership agreements for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL with TEVA in Israël.

The company is also developing other indications in solid tumors and certain orphan indications outside oncology. The company is currently launching a Phase II study in pancreas cancer and it exploring other solid tumor indications.

ERYTECH has its own GMP-approved and operational manufacturing site in Lyon (France), and a site for clinical production in Philadelphia (USA).

ERYTECH is listed on Euronext regulated market in Paris. (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharm. & Bio and Next Biotech indexes.

Forward-looking information

This document may contain forward-looking statements, forecasts and estimates ("Statements") with respect to the financial situation, the results of operations, the strategy, the project and to the anticipated future performance of ERYTECH Pharma. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amffrance.org), also available on our website (www.erytech.com) describe such risks and uncertainties for which ERYTECH Pharma makes no representations or warranty as to their accuracy or fairness. Furthermore, such Statements only speak as of the date of the publication of this document. ERYTECH disclaims any obligation to update any such Statements except to the extent required by French law.

For more information about Forward-looking information, please read Forward-looking information

This document may contain forward-looking statements and estimates with respect to the financial situation, the results of operations, the strategy, the project and to the anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of ERYTECH, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on our website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forwardlooking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by French law.

CONTACTS

ERYTECH

Gil Beyen Chairman & CEO Pierre-Olivier Goineau Vice President and COO Tel: +33 4 78 74 44 38 investors@erytech.com NewCap.

Julien Perez / Emmanuel Huynh Investor and press relations Tel: +33 1 44 71 98 52 erytech@newcap.fr

Code de champ modifié

Code de champ modifié

Code de champ modifié